Mallinckrodt has signed an agreement to purchase all outstanding shares of Sucampo Pharmaceuticals for around $1.2bn.
Under the agreement, Mallinckrodt will acquire Sucampo’s commercial and development assets, including the US Food and Drug Administration (FDA) approved AMITIZA (lubiprostone), which is a chloride channel activator developed for the treatment of constipation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In addition, Mallinckrodt will buy the global rights to RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% indicated for ocular hypertension and open-angle glaucoma in Japan.
Sucampo’s development assets include CPP-1X/sulindac and VTS-270, which is in Phase III development for Niemann-Pick type C (NPC).
Being developed under a collaborative agreement with Cancer Prevention Pharmaceuticals (CPP), CPP-1X/sulindac is currently under Phase III development to treat familial adenomatous polyposis (FAP).
Mallinckrodt CEO and president Mark Trudeau said: “The acquisition brings near-term net sales and earnings accretion through AMITIZA and supports our pipeline in rare diseases with VTS-270 and CPP-1X/sulindac.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company intends to leverage Sucampo’s existing commercial footprint for VTS-270 and CPP-1X/sulindac, and will utilise its own clinical and medical affairs infrastructure to support the approval and launch of these products.
Sucampo chairman and CEO Peter Greenleaf said: “With the addition of its significant resources and expertise, we believe Mallinckrodt is a natural partner to accelerate the development of our rare disease assets in NPC and FAP, and to continue to provide AMITIZA for patients suffering from constipation-related disorders.”
Subject to customary closing conditions, the transaction is expected to close in Q1 2018.
